TITLE:
Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors

CONDITION:
Breast Neoplasms

INTERVENTION:
Motexafin Gadolinium Injection

SUMMARY:

      The primary purpose of this study is to evaluate the safety, toxicities, and dosage for
      investigational drug Motexafin Gadolinium administered with docetaxel to patients with
      advanced solid tumors. Secondly, tumor response to the combined treatment will be evaluated.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -   18 years old

          -  Histologically or cytologically confirmed diagnosis of cancer (i.e., Unresectable
             locally advanced or metastatic non-small-cell lung carcinoma (NSCLC) that had
             progressed during or after one or more chemotherapy regimens; Metastatic breast
             cancer; Hormone-refractory prostate cancer; Recurrent or refractory ovarian cancer;
             Sarcoma)

          -  ECOG performance status score either 0 or 1

          -  Willing and able to provide written informed consent

        Exclusion Criteria:

        Laboratory Values of:

          -  Absolute neutrophil count < 2000/L

          -  Platelet count < 100,00/L

          -  AST or ALT > 1.5 x the upper limit of normal

          -  Alkaline phosphatase > 5 x the upper limit of normal

          -  Bilirubin > ULN

          -  Creatinine > 2.0 mg/dL

        and

          -  Peripheral neuropathy NCI CTC Grade 3 or higher

          -  Chemotherapy, radiation therapy, immunotherapy, or systemic biologic

          -  anticancer therapy within 21 days before beginning study treatment

          -  Known history of brain metastases or spinal cord compression

          -  Uncontrolled hypertension

          -  Myocardial infarction within 6 months before beginning study treatment

          -  Unstable angina pectoris, uncontrolled congestive heart failure, or uncontrolled
             serious arrhythmias

          -  Known sensitivity to or intolerable adverse effects from taxanes or polysorbate 80

          -  Known history of porphyria (testing not required at screening)

          -  Known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency (testing not
             required at screening)

          -  Known history of HIV infection (testing not required at screening)

          -  Female who is pregnant or lactating (pregnancy test is required for all female
             patients of childbearing potential)

          -  Female of childbearing potential or sexually active male unwilling to use adequate
             contraceptive protection

          -  Physical or mental condition that makes patient unable to complete specified
             follow-up assessments
      
